Patents by Inventor Shashank Mahashabde

Shashank Mahashabde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline composition containing escitalopram
    Patent number: 7420069
    Abstract: Crystalline particles of escitalopram oxalate with a particle size of at least 40 ?m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
    Type: Grant
    Filed: February 7, 2005
    Date of Patent: September 2, 2008
    Assignee: H. Lundbeck A/S
    Inventors: Troels Volsgaard Christensen, Ken Liljegren, Michiel Onne Elema, Lene Andresen, Shashank Mahashabde, Sebastian P. Assenza
  • Compositions Comprising Cyclohexylamines and Aminoadamantanes
    Publication number: 20070270500
    Abstract: The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.
    Type: Application
    Filed: November 5, 2004
    Publication date: November 22, 2007
    Inventors: Mahendra Dedhiya, Shashank Mahashabde, Yan Yang, Anshu Goel, Erhard Seiller, Bernhard Hauptmeier
  • Modified release formulations of memantine oral dosage forms
    Publication number: 20060051416
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: June 16, 2005
    Publication date: March 9, 2006
    Applicant: Forest Laboratories, Inc.
    Inventors: Suneel Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra Dedhiya, Shashank Mahashabde
  • Crystalline composition containing escitalopram
    Patent number: 6916941
    Abstract: Crystalline particles of escitalopram oxalate with a particle size of at least 40 ?m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: July 12, 2005
    Assignee: H. Lundbeck A/S
    Inventors: Troels Volsgaard Christensen, Ken Liljegren, Michiel Onne Elema, Lene Andresen, Shashank Mahashabde, Sebastian P. Assenza
  • Crystalline composition containing escitalopram
    Publication number: 20050147674
    Abstract: Crystalline particles of escitalopram oxalate with a particle size of at least 40 ?m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
    Type: Application
    Filed: February 7, 2005
    Publication date: July 7, 2005
    Inventors: Troels Christensen, Ken Liljegren, Michiel Elema, Lene Andresen, Shashank Mahashabde, Sebastian Assenza
  • Crystalline composition containing escitalopram
    Publication number: 20030212128
    Abstract: Crystalline particles of escitalopram oxalate with a particle size of at least 40 &mgr;m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
    Type: Application
    Filed: March 31, 2003
    Publication date: November 13, 2003
    Applicant: H. Lundbeck A/S
    Inventors: Troels Volsgaard Christensen, Ken Liljegren, Michiel Onne Elema, Lene Andresen, Shashank Mahashabde, Sebastian P. Assenza
  • Antifungal composition with enhanced bioavailability
    Publication number: 20030055067
    Abstract: A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: 1
    Type: Application
    Filed: April 1, 2002
    Publication date: March 20, 2003
    Applicant: SCHERING CORPORATION
    Inventors: Stefan Sharpe, Joel Sequeira, David Harris, Shashank Mahashabde